<?xml version="1.0" encoding="UTF-8"?>
<p id="p0235">Since the first H1N1 IAV vaccine was generated for prevention of the Spanish flu in 1938 by Jonas Salk and Thomas Francis [
 <xref rid="bib155" ref-type="bibr">155</xref>,
 <xref rid="bib156" ref-type="bibr">156</xref>], influenza vaccines have been improved dramatically. There are many types vaccines approved in US with trade names such as FluLaval, Fluarix, Agriflu, and Flublok. A live attenuated vaccine with the name of FluMist was approved by the Food and Drug Administration in US in 2003, and which is delivered through nasal spray [
 <xref rid="bib157" ref-type="bibr">157</xref>]. To decrease side effects, animal and insect cells were also approved to replace chicken embryos for growth of vaccine strain [
 <xref rid="bib158" ref-type="bibr">158</xref>]. To provide protection from most seasonal virus attacks using one shot, multiple dominant viruses were included into one vaccine, such as those containing 3 or 4 different circulating strains and called trivalent or quadrivalent vaccines [
 <xref rid="bib158" ref-type="bibr">158</xref>,
 <xref rid="bib159" ref-type="bibr">159</xref>]. Before a universal vaccine was successfully developed, it is necessary to switch vaccines strains year by year as the prevalent influenza viruses mutate their genes or change their subtypes very frequently to escape from the immune recognition [
 <xref rid="bib24" ref-type="bibr">24</xref>,
 <xref rid="bib29" ref-type="bibr">29</xref>].
</p>
